Progress in studies on antidiabetic agents

Yaoxue Xuebao

Volumn 36, Issue 9, 2001, Pages 711-715

  Tang, Lei ^a   Yang, Yu She ^a   Ji, Ru Yun ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Antidiabetic agent; Diabetes; Insulin sensitiser

Indexed keywords

ANTIDIABETIC AGENT; GLIMEPIRIDE; INSULIN; SULFONYLUREA DERIVATIVE;

ANIMAL; ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; HUMAN; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS;

ANIMALS; DIABETES MELLITUS, TYPE II; HUMAN; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; MOLECULAR STRUCTURE; SULFONYLUREA COMPOUNDS;

EID: 0041335381     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Shinkai H. Novel antidiabetic agents [P]. Exp Opin Ther Patents, 2000,10(1):59-66.
2. Perfetti R, Barnett PS, Mathur P, et al. Novel therapeutic strategies for the treatment of type 2 diabetes [J]. Diabetes Metab Rev, 1998,14(2):207-225.
3. Smits P, Thien T. Cardiovascular effects of sulphonylurea derivatives: implications for the treatment of NIDDM? [J]. Diobetologia, 1995,38(1):116-121.
4. Shinkai H, Toi H, Kumashiro I, et al. N-acylphenylalanines and related compounds: a new class of oral hypoglycemic agents [J]. J Med Chem, 1988,31(11): 2092-2097.
5. Shinkai H, Nishikawa M, Sato R, et al. N-(cyclohexylcarbonyl)-D-phenylalanines and related compounds: a new class of oral hypoglycemic agents.2 [J]. J Med Chem, 1989,32(7):1436-1441.
6. Ikenoue T, Akiyoshi M, Fujitani S, et al. Hypoglycemic and insulintropic effects of a novel oral antidiabetic agent, ( - )-N-(trans-4-isopropyl-cyclohexanecarbonyl)-D-phenylalanine (A-4166) [J]. Br J Pharmacol, 1997,120(1):137 -145.
7. Geisen K, Hübner M, Hitzel V, et al. Acylaminoalkyl-substituierte Benzoe- und Phenylalkansāuren mit Blutglukose-senkender Wirkung [J]. Arzneim-Forscht/Drug Res, 1978,28 (1):1081-1083.
8. Bell GI, Santerre RF, Mullenhach GT. Hamster preproglucagon contains the sequence of glucagon and related peptides [J]. Nature, 1983,302(5910):716-718.
9. aa-boro pro-dipeptides [J]. J Med Chem, 1996,39(10):2087-2094.
10. Hughes TE, Balkan B, Villhauer EB. NVP-DPP-728, a novel, orally active dipeptidyl peptide IV (DPP-IV) inhibitor, prevents glucagon-like peptide-1 (GIP-1) inactivation in rats [J]. Diabetes, 1999,48(suppl 1):A21.
11. Spiegelman BM. PPAR-γ: Adipogenic regulator and thiazolidinedione receptor [J]. Diabetes, 1998, 47(4):507 -514.
12. Sohda T, Mizuno K, Imamiya E, et al. Studies on antidiabetic agents. II. Synthesis of 5-[ 4-( 1-methylcyclohexyl-methoxy) benzyl] thiazolidine-2, 4-dione (ADD-3878) and its derivetives [J]. Chem Pharm Bull, 1982,30(10):3580-3600.
13. Yoshika T, Fujita T, Kanai T, et al. Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation [J]. J Med Chem, 1989,32(2):421-428.
14. Momose Y, Meguro K, Ikeda H, et al. Studies on antidiabetic agents. X. Synthesis and biological activities of pioglitazone and related compounds [J]. Chem Pharm Bull, 1991,39(6):1440-1445.
15. Oakes ND, Kennedy CJ, Jenkins AB, et al. A new antidiabetic agent, BRL-49653, reduces lipid availability and improve insulin action and glucoregulation in the rat [J]. Diabetes, 1994,43(10):1203-1210.
16. 2+ influx [J]. J Endocrinol, 1996,150(1):107 -111.
17. Henke BR, Blanchard SG, Brackeen MF, et al. N-(2-benzoylphenyl)-L-tyrosine PPAR γ agonists. 1 . Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents [J]. J Med Chem, 1998,41(25): 5020-5036.
18. Shinkai H, Onogi S, Tanaka M, et al. Isoazolidine-3, 5-dione and noncyclic 1, 3-dicarbonyl compounds as hypoglycemic agents [J]. J Med Chem, 1998,41(11):1927 -1933.
19. Buckle DR, Cantello BCC, Cawthorne MA, et al. Non thiazolidinedione anti-hyperglycemic agents, 1:α-Heteroatom substituted β-phenylpropanoic acids [J]. Bio Med Chem Lett, 1996,6(17):2121-2126.
20. Buckle DR, Cantello BCC, Cawthorne MA, et al. Non thiazolidinedione anti-hyperglycemic agents. 2: α-Carbon substituted β-phenylpropanoic acids [J]. Bio Med Chem Lett, 1996,6(17):2127-2130.
21. Murakami K, Tobe K, Ide T, et al. A novel insulin sensitiser acts as a coligand for peroxisome proliferator-activated receptor-α (PPAR-α) and PPAR-γ [J]. Diabetes, 1998,47(12):1841-1847.
22. Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids and eicosanoids are ligands for PPAR α and δ [J]. Proc Natl Acad Sci USA, 1997,94(9): 4312-4137.
23. Smith SA. Preparation of benzoxazole or pyridine derivatives as agonists of PPAR α and PPAR γ for the treatment of syndrome X [P]. WO: 9725042, 1997-07-17.
24. Pfahl M, Lernhardt W, Fanjol A. Methods and compositions for treating and/or preventing NIDDM using specific retinoid compounds [P]. WO: 9842340, 1998-10-01.
25. 3-adrenergic receptor [J]. Annu Rev Pharmacol Toxicol, 1997,37(4): 421-450.
26. 3-Adrenergic agonists [J]. Drugs Future, 1993, 18(6):529-549.
27. 3-adrenoceptors in a model of hypercholesterolemia [J]. IL Farmaco, 1999,54(5):710-712.
28. Hoover DJ, Lefkowttz-Snow S, Burgess-Henry JL, et al. Indole-2-carboxamide inhibitors of human liver glycogen phosphorylase [J]. J Med Chem, 1998, 41 (16):2934-2938.
29. Elchebly M, Payette P, Michaliszyn E, et al. Increased insulin sensitivity and obesity resistance in mice lacking the protein phosphatase-1B gene [J]. Science, 1999, 283 (5407):1544-1548.
30. Gimble JM, Robinson CE, Wu X, et al. Peroxisome proliferator-activated receptor gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells [J]. Mol Pharmacol, 1996, 50(5):1087-1094.
31. Lefebvre AT, Peinado-Onsurbe J, Leitersdorf I, et al. Regulation of lipoprotein metabolism by thiazolidines occurs through a distinct but complementary mechanism relative to fibrates [J]. Arterioscler Thromb Vasc Biol, 1997,17(9): 1756-1764.